Analyst Price Target is $49.50
▲ +120.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sigilon Therapeutics in the last 3 months. The average price target is $49.50, with a high forecast of $78.00 and a low forecast of $21.00. The average price target represents a 120.29% upside from the last price of $22.47.
Current Consensus is
The current consensus among 3 investment analysts is to hold stock in Sigilon Therapeutics. This Hold consensus rating has held steady for over two years.
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.